Image may be NSFW.
Clik here to view.
Ferring Pharmaceuticals inked a deal to acquire Rebiotix and its platform of living drugs for an undisclosed amount, the companies announced today.
The Roseville, Minn.-based company is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes.
Get the full story at our sister site, Drug Delivery Business News.
The post Ferring Pharma acquires Rebiotix and its microbiome therapy platform appeared first on MassDevice.
